moneyheap
RPRX · Analysis updated Nov 10, 2026, 6:00 PM ET
Why is Royalty Pharma plc (RPRX) stock moving?
Royalty Pharma reported Q3 2026 results on Nov 4 with adjusted EPS of $1.21, above the $1.18 estimate, and raised its full-year 2026 Portfolio Receipts guidance. Reported sales of $690M missed the $796.5M estimate, a gap that is a concern but has not weighed on the shares. On Nov 5 the company set a 2030 outlook of more than $4.7B in annual portfolio receipts and over $7.50 in portfolio cash flow per share, and Citigroup kept its Buy rating while raising its price target to $78. The Zymeworks update on Nov 9 mentions interest expense tied to a royalty-backed note with Royalty Pharma, which is a minor, indirect item. Price action supports the positive news: RPRX closed at $69.45 on Nov 10, up about 8.9% from $63.75 on Oct 22, and it is near its 30-day high of $69.77 set on Nov 5. Volume has been elevated around the earnings and outlook days (4.7M to 4.9M shares on Oct 30 and Nov 5) but eased to 3.4M on Nov 10, so the rally is not yet showing strong late-session volume. The stock is trading close to the Citigroup target of $78 less the gap, leaving limited immediate upside from the cited target alone.
News behind the analysis
- Royalty Pharma Mentioned in Zymeworks Q3 2026 Financial ResultsZymeworks said its Q3 2026 results were affected by interest expense on a royalty-backed note financing with Royalty Pharma.
- Royalty Pharma Announces 2030 Financial OutlookRoyalty Pharma targets more than $4.7 billion in annual portfolio receipts and over $7.50 in portfolio cash flow per share by 2030.
- Citigroup Maintains Buy on Royalty Pharma, Raises Price Target to $78Citigroup kept its Buy rating on Royalty Pharma and raised its price target to $78.
- Royalty Pharma Reports Third Quarter 2026 Financial Results and Raises Full Year GuidanceRoyalty Pharma reported Q3 2026 results and raised its full-year 2026 guidance for Portfolio Receipts.
- Royalty Pharma Q3 Adj. EPS $1.21 Beats $1.18 Estimate, Sales $690.000M Miss $796.528M EstimateAdjusted EPS of $1.21 beat the $1.18 estimate, while reported sales of $690M came in below the $796.5M estimate.
- Here's How Much $100 Invested In Royalty Pharma 10 Years Ago Would Be Worth TodayBenzinga reports Royalty Pharma has outperformed the market over 10 years by 32.09% annualized, with an average annual return of 45.51%.
About Royalty Pharma plc Class A Ordinary Shares
Royalty Pharma buys royalties on biopharmaceutical products, making it the largest buyer of these royalties. It doesn't discover or sell drugs itself. Instead, it pays drug developers, universities and other royalty holders upfront cash in return for a share of future sales, so it holds a diversified portfolio of rights to drugs such as cystic fibrosis treatments from Vertex, Trelegy, Tremfya and Evrysdi.
How it makes money
Nearly all of its cash comes from royalty receipts, which are a percentage of sales of drugs that other companies sell. In Q3 2026 it collected about $883 million in royalties out of roughly $890 million in total portfolio receipts. The rest comes from milestone and other contractual payments. For full-year 2026 the company guides to about $3.5–3.55 billion in portfolio receipts. It puts that cash into new royalty deals (recent ones cover drugs such as Zoryve, cliramitug and rusfertide), pays down debt and interest (about $350–360 million in 2026) and pays a quarterly dividend (about $0.235 per share).
What usually moves RPRX
- Sales trends of key royalty drugs (e.g., Vertex CF franchise, Trelegy, Tremfya)
- Pace and pricing of new royalty acquisitions
- Clinical trial and regulatory outcomes for development-stage royalties
- Patent expirations and competition for royalty-bearing drugs
- Interest rates and financing costs